MX385941B - Uso de cd24 para disminuir los niveles de colesterol de las lipoproteínas de baja densidad. - Google Patents

Uso de cd24 para disminuir los niveles de colesterol de las lipoproteínas de baja densidad.

Info

Publication number
MX385941B
MX385941B MX2017014095A MX2017014095A MX385941B MX 385941 B MX385941 B MX 385941B MX 2017014095 A MX2017014095 A MX 2017014095A MX 2017014095 A MX2017014095 A MX 2017014095A MX 385941 B MX385941 B MX 385941B
Authority
MX
Mexico
Prior art keywords
density lipoprotein
cholesterol levels
lipoprotein cholesterol
lower low
low
Prior art date
Application number
MX2017014095A
Other languages
English (en)
Spanish (es)
Other versions
MX2017014095A (es
Inventor
Pan Zheng
Yang Liu
Original Assignee
Oncoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc filed Critical Oncoimmune Inc
Publication of MX2017014095A publication Critical patent/MX2017014095A/es
Publication of MX385941B publication Critical patent/MX385941B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
MX2017014095A 2015-05-07 2016-05-06 Uso de cd24 para disminuir los niveles de colesterol de las lipoproteínas de baja densidad. MX385941B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562158157P 2015-05-07 2015-05-07
PCT/US2016/031109 WO2016179456A1 (en) 2015-05-07 2016-05-06 Use of cd24 for lowering low-density lipoprotein cholesterol levels

Publications (2)

Publication Number Publication Date
MX2017014095A MX2017014095A (es) 2018-03-16
MX385941B true MX385941B (es) 2025-03-18

Family

ID=57218627

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014095A MX385941B (es) 2015-05-07 2016-05-06 Uso de cd24 para disminuir los niveles de colesterol de las lipoproteínas de baja densidad.

Country Status (18)

Country Link
US (2) US10369197B2 (https=)
EP (1) EP3292144B1 (https=)
JP (1) JP6751756B2 (https=)
KR (1) KR20170141216A (https=)
CN (1) CN107531772B (https=)
AU (1) AU2016258084B2 (https=)
BR (1) BR112017022394A2 (https=)
CA (1) CA2982612A1 (https=)
EA (1) EA038520B1 (https=)
ES (1) ES2829235T3 (https=)
HK (1) HK1249521A1 (https=)
HR (1) HRP20201651T1 (https=)
HU (1) HUE051866T2 (https=)
IL (1) IL255086B (https=)
MX (1) MX385941B (https=)
PT (1) PT3292144T (https=)
WO (1) WO2016179456A1 (https=)
ZA (1) ZA201706846B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017022394A2 (pt) * 2015-05-07 2018-07-17 Oncoimmune Inc uso de cd24 para diminuir níveis de colesterol das lipoproteínas de baixa densidade
WO2018165204A1 (en) * 2017-03-07 2018-09-13 Oncoimmune, Inc. Methods of use of soluble cd24 for treating systemic lupus erythematosus
WO2019113123A1 (en) * 2017-12-04 2019-06-13 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
JP2021523929A (ja) * 2018-03-05 2021-09-09 オンコイミューン， インコーポレイテッド 後天性免疫不全症候群（ｈｉｖ／ａｉｄｓ）の治療のための可溶性ｃｄ２４の使用方法
WO2019236474A1 (en) * 2018-06-04 2019-12-12 Oncoimmune, Inc. Methods of use of cd24 for the prevention and treatment of leukemia relapse
EP3870604B1 (en) 2018-10-26 2022-11-23 F. Hoffmann-La Roche AG Multispecific antibody screening method using recombinase mediated cassette exchange
EP3921338A4 (en) * 2019-02-06 2022-11-23 Oncoimmune Inc. TARGETED CD24-SIGLEC INTERACTIONS TO TREAT AND PREVENT NON-ALCOHOLIC STEATOHEPATITIS
US20220000974A1 (en) * 2019-02-06 2022-01-06 Oncolmmune, Inc. Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes
WO2021160173A1 (en) * 2020-02-10 2021-08-19 Oncoimmune, Inc. Methods of use of soluble cd24 for treating viral pneumonia
WO2021160170A1 (en) * 2020-02-10 2021-08-19 Oncoimmune, Inc. Methods of use of soluble cd24 for treating sars-cov-2 infection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544566B1 (en) * 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
EP1267909B1 (en) * 2000-03-29 2010-07-28 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive t cells
CN1323544A (zh) * 2000-05-13 2001-11-28 蛋白质技术国际公司 降低低密度脂蛋白胆固醇浓度的组合物和方法
US20110002846A1 (en) * 2007-12-21 2011-01-06 Univeristy of Rochester Cd24 as a brain tumor stem cell marker and a diagnostic and therapeutic target in primary neural and glial tumors of the brain
US8163281B2 (en) * 2009-03-04 2012-04-24 The Regents Of The University Of Michigan Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
US8354520B2 (en) * 2009-12-10 2013-01-15 Kaohsiung Medical University Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug
DK2563385T3 (da) * 2010-04-28 2017-11-06 Oncoimmune Inc Fremgangsmåder til anvendelse af opløselig cd24 til behandling af reumatoid artritis
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
AU2012267489B2 (en) * 2011-06-10 2017-03-16 The Trustees Of The University Of Pennsylvania System and method of cytomic vascular health profiling
BR112017022394A2 (pt) * 2015-05-07 2018-07-17 Oncoimmune Inc uso de cd24 para diminuir níveis de colesterol das lipoproteínas de baixa densidade

Also Published As

Publication number Publication date
CA2982612A1 (en) 2016-11-10
EA201792418A1 (ru) 2018-02-28
AU2016258084B2 (en) 2020-01-30
ES2829235T3 (es) 2021-05-31
WO2016179456A1 (en) 2016-11-10
US11026995B2 (en) 2021-06-08
US10369197B2 (en) 2019-08-06
EP3292144A4 (en) 2018-11-14
US20190307841A1 (en) 2019-10-10
EP3292144B1 (en) 2020-08-26
AU2016258084A1 (en) 2017-11-02
JP2018515605A (ja) 2018-06-14
EP3292144A1 (en) 2018-03-14
PT3292144T (pt) 2020-11-05
IL255086A0 (en) 2017-12-31
HUE051866T2 (hu) 2021-03-29
CN107531772B (zh) 2021-09-21
BR112017022394A2 (pt) 2018-07-17
ZA201706846B (en) 2018-12-19
HK1249521A1 (zh) 2018-11-02
HRP20201651T1 (hr) 2020-12-25
KR20170141216A (ko) 2017-12-22
MX2017014095A (es) 2018-03-16
IL255086B (en) 2021-08-31
JP6751756B2 (ja) 2020-09-09
EA038520B1 (ru) 2021-09-09
CN107531772A (zh) 2018-01-02
US20180110828A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
MX385941B (es) Uso de cd24 para disminuir los niveles de colesterol de las lipoproteínas de baja densidad.
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
EP3538078A4 (en) FORMULATIONS FOR EFFICIENT CANNABINOID DELIVERY
BR112016029864A2 (pt) métodos e dispositivos para tratamento de desordens oculares posteriores.
MX2018000778A (es) Metodos para tratar trastornos mediados por hepcidinas.
EP3636246A4 (en) COSMETIC PREPARATION WITH WATER-IN-OIL EMULSION
CU20150094A7 (es) Imidazopiridazinas sustituídas
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
EP3530264A4 (en) OIL-IN-WATER-TYPE EMULSION COMPOSITION
AR093939A1 (es) Composiciones que comprenden vortioxetina y donepezil
MX382116B (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
MX392383B (es) Metodos para tratar afecciones oculares.
DK3544598T3 (da) Cannabinoider til profylaktisk behandling af ufrivilligt vægttab
CL2018003792A1 (es) Procedimiento para enfriamineto de elementos de madera acetilada.
BR112018076619A2 (pt) composições antimalariais e usos das mesmas
BR112018074820A2 (pt) surfactantes não iónicos para a redução de tecido adiposo
MX2017013729A (es) Deteccion especifica de isoformas de clusterina.
BR112017019154A2 (pt) uso de frações isoladas de goma mástica para o tratamento de neuropatia óptica
EP3733160A4 (en) EMULSIFIED COMPOSITION
EP3991565C0 (en) EMULSIFIED COMPOSITION WATER IN OIL
MX367732B (es) Tratamiento o prevencion de queratosis seborreica utilizando artemisinina y derivados de la misma.
LT3519050T (lt) Kompozicijos, skirtos oftalmologinių būklių gydymui
ES1196108Y (es) Estructura de juego de mesa para rehabilitacion del lenguaje
MX380683B (es) Lisobactina para su uso en el tratamiento de la mastitis bovina.
MX2016010967A (es) Nuevas composiciones para tratar lesiones neuronales mecanicas.